Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Bimoclomol and Arimoclomol: HSP-co-Inducers for the Treatment of Protein Misfolding Disorders, Neuropathy and Neuropathic Pain

Keppel Hesselink JM*

Department of Molecular Pharmacology, Pain Specialist, Faculty of Health, University of Witten, Germany

*Corresponding Author:
Keppel Hesselink JM
Faculty of Health, University of Witten/Herdecke, Germany
Tel: 06-51700527
E-mail: jan@neuropathie.nu

Received date: November 21, 2016; Accepted date: December 23, 2016; Published date: December 27, 2016

Citation: Keppel Hesselink JM (2016) Bimoclomol and Arimoclomol: HSP-co-Inducers for the Treatment of Protein Misfolding Disorders, Neuropathy and Neuropathic Pain. J Pain Relief 6:279. doi:10.4172/2167-0846.1000279

Copyright: © 2016 Keppel Hesselink JM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Bimoclomol and arimoclomol are small new chemical entities which have been synthesized during the end of last century by a Hungarian pharmaceutical company, Biorex. Both compounds consistently increase Heat Shock Protein (HSP) expression and reduce functional as well as structural pathology in a series of animal models. The development of bimoclomol stagnated, most probably due the short half life time of the compound. Arimoclomol is currently in development for orphan disorders such as amyotrophic lateral sclerosis, the sphingolipidose Niemann- Pick type C and inclusion body myositis. Arimoclomol has high oral availability and good CNS penetration, without inducing troublesome CNS side effects. It might also be a promising compound for the treatment of diabetic neuropathy and neuropathic pain in (diabetic) neuropathy, due to its neuroprotective and analgesic properties.

Keywords

Recommended Conferences
Google Scholar citation report
Citations : 1131

Journal of Pain & Relief received 1131 citations as per Google Scholar report

Journal of Pain & Relief peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • Genamics JournalSeek
  • Cosmos IF
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Share This Page
Top